Nexalin Neurostimulation Data Validates Approach, Bolsters Insomnia Treatment Pipeline

Event summary

  • Nexalin published a peer-reviewed study in Psychotherapy and Psychosomatics on April 20, 2026, detailing clinical improvements in chronic insomnia patients.
  • The study showed a statistically significant reduction in PSQI scores (from 13.8 to 7.7) in the active treatment group versus no change in the sham group (13.8 to 13.9).
  • Neuroimaging data indicated measurable modulation of brain networks (Default and Salience/Ventral Attention networks) associated with hyperarousal and emotional regulation.
  • The publication supports Nexalin’s proprietary DIFS™ technology and its non-pharmacological treatment strategy for mental health issues.
  • Nexalin is advancing the HALO™ Clarity pivotal program, intended to support a De Novo FDA submission in insomnia.

The big picture

Nexalin’s publication represents a step towards validating non-pharmacological interventions for mental health, a market increasingly pressured to find alternatives to traditional drug therapies. The company’s focus on neuroimaging data to support its claims is a strategic differentiator, but the success of its De Novo FDA pathway and subsequent commercial adoption will determine its long-term viability. The broader neurostimulation market is attracting significant investment, and Nexalin’s ability to demonstrate superior efficacy and safety will be key to capturing market share.

What we're watching

Regulatory Pathway
The success of the HALO™ Clarity pivotal program and subsequent De Novo FDA submission will be critical for Nexalin’s commercialization timeline and market access.
Clinical Replication
Whether the observed brain network modulation and clinical improvements can be consistently replicated in larger, more diverse patient populations remains to be seen.
Competitive Landscape
The emergence of competing non-pharmacological treatments for insomnia and other neuropsychiatric conditions could erode Nexalin’s differentiated position and pricing power.

Related topics

Biotechnology Clinical Trial Medical Devices